Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (c-MET) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(Quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the Treatment of Cancer

Factor C ◽

Mesenchymal Epithelial Transition ◽

Clinical Candidate

Faculty Opinions recommendation of Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717967633.793467413 ◽

2012 ◽

Author(s):

Donald Pinto

Keyword(s):

Protein Kinase ◽

Kinase Inhibitors ◽

Factor C ◽

Mesenchymal Epithelial Transition ◽

Clinical Candidate

Correction to Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (c-MET) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(Quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the Treatment of Cancer

Journal of Medicinal Chemistry ◽

10.1021/jm3014647 ◽

2012 ◽

Vol 55 (22) ◽

pp. 10314-10314 ◽

Cited By ~ 2

Author(s):

J. Jean Cui ◽

Michele McTigue ◽

Mitchell Nambu ◽

Michelle Tran-Dubé ◽

Mason Pairish ◽

...

Keyword(s):

Protein Kinase ◽

Kinase Inhibitors ◽

Factor C ◽

Mesenchymal Epithelial Transition ◽

Clinical Candidate

Erratum to “Discovery and optimization of a series of imidazo[4,5-b]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymal–epithelial transition factor (c-Met) protein kinase” [Bioorg. Med. Chem. 24 (2016) 4281–4290]

Bioorganic & Medicinal Chemistry ◽

10.1016/j.bmc.2017.03.042 ◽

2017 ◽

Vol 25 (10) ◽

pp. 2811-2812

Author(s):

Fei Zhao ◽

Jing Zhang ◽

Leduo Zhang ◽

Yu Hao ◽

Chen Shi ◽

...

Keyword(s):

Protein Kinase ◽

Selective Inhibitors ◽

Factor C ◽

Discovery and optimization of a series of imidazo[4,5-b]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymal–epithelial transition factor (c-Met) protein kinase

Bioorganic & Medicinal Chemistry ◽

10.1016/j.bmc.2016.07.019 ◽

2016 ◽

Vol 24 (18) ◽

pp. 4281-4290 ◽

Cited By ~ 10

Author(s):

Fei Zhao ◽

Jing Zhang ◽

Leduo Zhang ◽

Yu Hao ◽

Chen Shi ◽

...

Keyword(s):

Protein Kinase ◽

Selective Inhibitors ◽

Factor C ◽

Discovery of a Novel Mode of Protein Kinase Inhibition Characterized by the Mechanism of Inhibition of Human Mesenchymal-epithelial Transition Factor (c-Met) Protein Autophosphorylation by ARQ 197

Journal of Biological Chemistry ◽

10.1074/jbc.m110.213801 ◽

2011 ◽

Vol 286 (23) ◽

pp. 20666-20676 ◽

Cited By ~ 94

Author(s):

Sudharshan Eathiraj ◽

Rocio Palma ◽

Erika Volckova ◽

Marscha Hirschi ◽

Dennis S. France ◽

...

Keyword(s):

Protein Kinase ◽

Kinase Inhibition ◽

Protein Kinase Inhibition ◽

Mechanism Of Inhibition ◽

Arq 197 ◽

Factor C ◽

Faculty Opinions recommendation of Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.12934957.14822055 ◽

2012 ◽

Author(s):

John Proudfoot

Keyword(s):

Drug Design ◽

Anaplastic Lymphoma Kinase ◽

Dual Inhibitor ◽

Structure Based Drug Design ◽

Anaplastic Lymphoma ◽

Factor C ◽

Faculty Opinions recommendation of Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.12934957.14323054 ◽

2011 ◽

Author(s):

John Lowe

Keyword(s):

Drug Design ◽

Anaplastic Lymphoma Kinase ◽

Dual Inhibitor ◽

Structure Based Drug Design ◽

Anaplastic Lymphoma ◽

Factor C ◽

Faculty Opinions recommendation of Re-positioning protein-kinase inhibitors against schistosomiasis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725849707.793510456 ◽

2015 ◽

Author(s):

William Evan Secor

Keyword(s):

Protein Kinase ◽

Kinase Inhibitors ◽

Protein Kinase Inhibitors

In silico Modeling of Antimalarial Protein Kinase Inhibitors

Letters in Drug Design & Discovery ◽

10.2174/1570180812666150723000621 ◽

2015 ◽

Vol 13 (2) ◽

pp. 129-134 ◽

Cited By ~ 1

Author(s):

Rahul Balasaheb Aher ◽

Kunal Roy

Keyword(s):

Protein Kinase ◽

In Silico ◽

Kinase Inhibitors ◽

In Silico Modeling

Thiazolidine-diones. Biochemical and biological activity of a novel class of tyrosine protein kinase inhibitors.

Journal of Biological Chemistry ◽

10.1016/s0021-9258(18)45697-9 ◽

1990 ◽

Vol 265 (36) ◽

pp. 22255-22261

Author(s):

J F Geissler ◽

P Traxler ◽

U Regenass ◽

B J Murray ◽

J L Roesel ◽

...

Keyword(s):

Biological Activity ◽

Protein Kinase ◽

Kinase Inhibitors ◽

Tyrosine Protein Kinase